Lidia Oostvogels Selected Research

Herpes Zoster Vaccine

1/2021	Recombinant Zoster Vaccine Is Efficacious and Safe in Frail Individuals.
11/2020	Post hoc analysis of reactogenicity trends between dose 1 and dose 2 of the adjuvanted recombinant zoster vaccine in two parallel randomized trials.
12/2019	Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT).
12/2019	Quality of Life Impact of an Adjuvanted Recombinant Zoster Vaccine in Adults Aged 50 Years and Older.
1/2019	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis.
1/2019	Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in patients with solid tumors, vaccinated before or during chemotherapy: A randomized trial.
1/2019	The adjuvanted recombinant zoster vaccine co-administered with a tetanus, diphtheria and pertussis vaccine in adults aged ≥50 years: A randomized trial.
1/2019	Medical conditions at enrollment do not impact efficacy and safety of the adjuvanted recombinant zoster vaccine: a pooled post-hoc analysis of two parallel randomized trials.
1/2019	Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial.
1/2019	Safety profile of the adjuvanted recombinant zoster vaccine: Pooled analysis of two large randomised phase 3 trials.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lidia Oostvogels Research Topics

Disease

18	Herpes Zoster 01/2021 - 04/2015
7	Human Influenza (Influenza) 12/2016 - 06/2013
4	Pain (Aches) 12/2019 - 01/2019
2	COVID-19 08/2022 - 01/2022
2	Frailty 01/2021 - 01/2019
2	Neoplasms (Cancer) 01/2019 - 01/2019
2	Postherpetic Neuralgia 01/2019 - 09/2016
1	Infections 08/2022
1	HIV Infections (HIV Infection) 01/2022
1	Multiple Myeloma 11/2021
1	Rabies (Hydrophobia) 01/2021
1	B-Cell Lymphoma (Lymphoma, B Cell) 01/2019
1	Fatigue 01/2019
1	Diphtheria 01/2019
1	Injection Site Reaction 01/2019
1	Tetanus 01/2019
1	Pneumonia (Pneumonitis) 06/2014

Drug/Important Bio-Agent (IBA)

17	VaccinesIBA 01/2022 - 06/2013
13	Herpes Zoster VaccineIBA 01/2021 - 10/2017
7	Influenza Vaccines (Influenza Vaccine)FDA Link 12/2017 - 06/2013
5	Subunit VaccinesIBA 01/2018 - 09/2016
3	AS01B adjuvantIBA 01/2018 - 09/2016
3	varicella-zoster virus glycoprotein EIBA 01/2018 - 09/2016
2	Messenger RNA (mRNA)IBA 01/2022 - 01/2022
2	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 07/2014 - 06/2014
1	SARS-CoV-2 spike proteinIBA 08/2022
1	Neutralizing AntibodiesIBA 01/2021
1	insulin receptor-related receptor (IRR)IBA 01/2019
1	Glycoproteins (Glycoprotein)IBA 01/2019
1	Pertussis VaccineIBA 01/2019
1	Hemagglutinins (Hemagglutinin)IBA 04/2015
1	Interleukin-2 (IL2)IBA 07/2014
1	AS03 adjuvantIBA 07/2014
1	Biomarkers (Surrogate Marker)IBA 07/2014
1	CD40 Ligand (CD40L)IBA 07/2014
1	AntigensIBA 07/2014
1	RNA (Ribonucleic Acid)IBA 06/2013

Therapy/Procedure

2	Activities of Daily Living (ADL) 12/2019 - 12/2019
1	Stem Cell Transplantation 01/2019
1	Drug Therapy (Chemotherapy) 01/2019
1	Hematopoietic Stem Cell Transplantation 01/2019
1	Art Therapy 04/2015